Patrick Gunning & Diana Kraskouskaya win the RBC Prize for Innovation and Entrepreneurship for D

A novel therapeutic that has been shown in advanced pre-clinical studies to target cancer without the toxic side effects of treatments like chemotherapy has earned the Gunning Group the top prize in a new business pitch competition. Established to reward and accelerate U of T’s innovative technologies and start-ups, the RBC Prize for Innovation and Entrepreneurship was presented to Dalriada Therapeutics, a company co-founded by Professor Gunning. He and his team plan to use the $25,000 prize to further investigate the potential applications of the therapeutic, called DT1, on a range of cancers, including acute myeloid leukemia and glioblastoma, an aggressive, hard-to-treat cancer that begins within the brain.